2022
Nanoparticle-based drug delivery for the treatment of traumatic brain injury
Mohammed F, Omay S, Sheth K, Zhou J. Nanoparticle-based drug delivery for the treatment of traumatic brain injury. Expert Opinion On Drug Delivery 2022, 20: 55-73. PMID: 36420918, PMCID: PMC9983310, DOI: 10.1080/17425247.2023.2152001.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryBrain injurySecondary outcomesClinical trialsPathophysiology of TBIPhase III clinical trialsPhase II clinical trialClinical management strategiesSite of injuryOff-target toxicityPharmacological treatmentBrain penetrationLow off-target toxicityExperimental animalsInjuryChronic timescalesDosage thresholdDrug deliveryTrialsDrug targetingOutcomesTreatmentDeliveryPathophysiologyChapter 55 Non-neoplastic mass lesions of the central nervous system
Karschnia P, Omay S, Fulbright R, Baehring J. Chapter 55 Non-neoplastic mass lesions of the central nervous system. 2022, 795-808. DOI: 10.1016/b978-0-12-822835-7.00043-3.Peer-Reviewed Original ResearchNon-neoplastic mass lesionsCentral nervous systemMass lesionNervous systemNon-neoplastic lesionsInvasive diagnostic proceduresAnti-tumor treatmentSpecific imaging modalityMimic malignancyUnnecessary treatmentNeurosurgical interventionNeoplastic lesionsPatient managementAdvanced imagingAccurate diagnosisLesionsDiagnostic proceduresImaging modalitiesDiagnosisModalitiesTreatmentMalignancyPrognosisEtiology
2016
Chapter 53 Nonneoplastic Mass Lesions of the Central Nervous System
Omay S, Atsina K, Baehring J. Chapter 53 Nonneoplastic Mass Lesions of the Central Nervous System. 2016, 653-665. DOI: 10.1016/b978-0-12-800945-1.00053-7.Peer-Reviewed Original Research